Dopamine is administered frequently in the operating theatre and intensive care unit patients undergoing mechanical ventilation with the aim of specifically enhancing renal blood flow. ) during a 1-h period each. Systemic haemodynamic and renal haemodynamic variables were measured simultaneously using a pulmonary artery catheter and radiopharmaceuticals, respectively. We studied seven haemodynamically stable patients (mean age 66 yr), with a serum creatinine concentration : 160 mol litre
Summary
Dopamine is administered frequently in the operating theatre and intensive care unit patients undergoing mechanical ventilation with the aim of specifically enhancing renal blood flow. ) during a 1-h period each. Systemic haemodynamic and renal haemodynamic variables were measured simultaneously using a pulmonary artery catheter and radiopharmaceuticals, respectively. We studied seven haemodynamically stable patients (mean age 66 yr), with a serum creatinine concentration : 160 mol litre
91
, after elective infrarenal abdominal aortic reconstruction. All patients received extradural analgesia with bupivacaine and sufentanil, and none had a previous history of heart failure. Dopamine induced a dose-dependent increase in cardiac index which returned to baseline after cessation of the dopamine infusion. Glomerular filtration rate (GFR) increased with all doses of dopamine, whereas renal blood flow (RBF) increased significantly only with the 2-and 4-g kg Dopamine, a naturally occurring catecholamine, has a complicated influence on the cardiovascular and renal systems. This is because dopamine stimulates different types of adrenergic receptors: not only ␣-and ␤-adrenergic but also specific dopamine receptors.
1 Dopamine can be used for various indications depending on the given dose. In doses of 0.5-3.0 g kg 91 min
, the so-called "renal dose", the predominant effect of dopamine is a marked increase in renal plasma flow, glomerular filtration rate and sodium excretion. This is caused mainly by stimulation of dopamine receptors. In doses of 3-10 g kg 91 min 91 , dopamine exerts positive inotropic effects, primarily as a result of ␤1 receptor stimulation. In doses exceeding 10 g kg 91 min
, dopamine induces vasoconstriction and positive chronotropism as a result of predominant ␣-adrenergic and ␤-adrenergic effects, respectively.
Alterations in renal blood flow may contribute to the initiation of events which lead to renal failure. 2 In the intensive care unit dopamine is often used in doses of up to 4 g kg 91 min 91 to increase or preserve renal blood flow. In clinical practice dopamine is given during mechanical ventilation, particularly during positive end-expiratory pressure (PEEP) ventilation for this purpose. Cardiac output is decreased during PEEP, 3 4 leading to decreased renal blood flow. Furthermore, PEEP decreases the release of atrial natriuretic peptide. 5 The renal vasodilating and natriuretic properties of a low-dose infusion of dopamine are therefore believed to be beneficial.
In previous studies in healthy subjects and patients with congestive heart failure (CHF) we and others have demonstrated that renal blood flow and sodium excretion are increased by administration of dopamine or its analogues. [6] [7] [8] [9] [10] However, there are no clinical studies on the renal haemodynamic effects of different "low-dose" dopamine infusions during mechanical ventilation with PEEP and their relation to systemic haemodynamics. As cardiac output and venous return are altered significantly during mechanical ventilation, it is reasonable to argue that renal haemodynamics and the effects of low-dose dopamine may be different from results obtained in healthy volunteers and patients with CHF.
In our department patients are admitted after major vascular surgery where sedation and A. R. J. GIRBES, MD Patients receiving either ␣-or ␤-adrenergic agonists or antagonists, dopamine agonists or antagonists, monoamine oxidase inhibitors, angiotensin converting enzyme inhibitors or diuretics in the previous 3 months were excluded. Patients with a previous history of congestive heart failure were also excluded. All patients had a pulmonary artery catheter (Baxter Thermodilution Catheter, Edwards Laboratories, Irvine, CA, USA) inserted before operation for peroperative monitoring. The position was checked in the ICU by a standard chest roentgenogram. All patients had an extradural infusion of a combination of 0.125% bupivacaine and sufentanil 1 g ml 91 at a rate of 8 ml h 91 for analgesia. Additional sedation comprised a continuous infusion of midazolam during the study. An infusion of 0.45%-2.5% sodium-glucose was given at a rate of 3500 ml day
. Potassium was administered according to serum potassium concentrations. Initially, supplements of crystalloids and colloids were given in the immediate postoperative phase and (mild) hypothermia was corrected. At the moment when no inotropic support and no additional rapid fluid infusion were required, the study was started. All patients gave written informed consent and the study was approved by the Medical Ethics Committee of the University Hospital of Groningen.
After haemodynamic stability was established and patients were normothermic, measurements were started after a further equilibration period of 1.5-2 h. After 1 h of baseline measurements, an infusion of dopamine was started. During the first hour the rate of infusion was 2 g kg 91 min
. In the second and third hours this dose was increased to 4 and 8 g kg 91 min
, respectively. During the fourth hour the dopamine infusion was decreased gradually over 10 min. At the end of this hour the study was terminated.
RENAL FUNCTION TESTS
Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured simultaneously using 125 I-iothalamate and 131 I-hippurate, respectively, according to the method described by Donker and colleagues. 11 The radiopharmaceuticals were infused at a constant rate after a priming dose had been given. After the previously mentioned equilibration period of 1.5-2 h, clearances were determined every hour. Filtration fraction (FF) represents the ratio GFR/ERPF. Hourly urine samples were collected via a bladder catheter. Serum and urinary electrolyte concentrations were assayed by routine Technicon SMA-C Auto-Analyzer (Technicon, Tarrytown, NY, USA). After measurements of baseline values during the first hour, hourly measurements were performed during the subsequent 4 h.
HAEMODYNAMIC MEASUREMENTS
Using the pulmonary artery catheter, inserted via the jugular vein, cardiac output, pulmonary capillary wedge, pulmonary arterial and central venous pressures were measured every 30 min. Haemodynamic measurements and derived variables were determined as described previously. 12 Arterial pressure was measured via a radial arterial cannula. Haemodynamic data were measured together with renal function tests, thereby allowing simultaneous evaluation of the renal and systemic haemodynamic effects of dopamine.
PLASMA NEUROHUMORAL VARIABLES
Blood samples were obtained for measurement of plasma renin activity (PRA) and plasma aldosterone concentration (PAC) at the end of each hour during the study. PRA and PAC were determined by radioimmunoassay. The intra-assay coefficients of variation were 5.2% and 8% for PRA and PAC, respectively. The inter-assay coefficient of variation was 15% for PAC and 10.3% for PRA. Serum catecholamine concentrations were determined by high pressure liquid chromatography (HPLC) with electrochemical detection, after an extraction procedure. 13 
STATISTICAL ANALYSIS
All data are given as mean (SEM), unless otherwise stated. Paired statistics were performed comparing baseline values with values at specific times, which means that every patient served as his own control. Paired t tests were used for normally distributed data, whereas the Wilcoxon test was used for non-normally distributed data. The software package SPSS for Windows, version 6.0 was used on a 486 DX personal computer. For non-normally distributed data, medians and ranges are given. All values for ERPF and GFR were corrected for a body surface of 1.73 m 2 . Renal blood flow (RBF) was calculated as (uncorrected ERPF)/(1 9 packed cell volume). The percentage renal blood flow-cardiac output (CO) ratio was calculated as RBF/CO 100%. Differences were considered statistically significant at the 5% level.
Results
We studied six males and one female, mean age 66 (range 46-77) yr. All underwent uncomplicated infrarenal abdominal aortic reconstruction. . Sodium concentration and fractional sodium excretion increased in a dose-dependent manner from 11.9 (3.7) mmol h 91 and 0.09 (0.03)% to 36.0 (7.5) mmol h 91 and 0.24 (0.05) %, respectively. All returned to values comparable with baseline at the end of the study when dopamine was stopped.
NEUROHORMONES AND CATECHOLAMINES (TABLE 3) There were no significant changes in PRA during the study. Plasma concentrations of aldosterone were reduced significantly by dopamine 8 g kg 91 min
91
. Median plasma concentrations of noradrenaline were increased significantly by dopamine infusion. After stopping dopamine, plasma concentrations of noradrenaline returned to values comparable with . After stopping the infusion of dopamine, plasma concentrations of dopamine decreased to 11.9 (7.6-326) nmol litre 91 .
Discussion
We found that although dopamine increased GFR and RBF at different doses, no specific enhancement of renal flow was present. The increase in RBF was caused mainly by an increase in cardiac output. With dopamine 8 g kg 91 min
91
, the fraction of cardiac output directed to the kidney was even decreased. Furthermore, dopamine acted as a diuretic in a dose-dependent manner, with an increase in diuresis and (fractional) sodium excretion. The decrease in plasma concentration of aldosterone, which may also have contributed to the natriuretic effect of dopamine, was related probably to dopamine DA2 receptor stimulation of the adrenal zona glomerulosa. 14 15 Dopamine is frequently administered in the ICU to patients undergoing mechanical ventilation to improve GFR and RBF. An improvement in mainly RBF has been shown in many studies investigating healthy volunteers or non-mechanically ventilated patients with congestive heart failure. 6 8 16-18 However, few data exist indicating an increase in renal perfusion in patients undergoing mechanical ventilation. Mostly, only estimates of renal function, such as creatinine clearance and diuresis are measured. 19 20 Additionally, in most studies the ␤-agonist activity of dopamine is insufficiently regarded, as cardiac output is not measured simultaneously.
Despite the frequently used terminology "renal dose" of dopamine, indicating a dose of dopamine with preferential effects on renal haemodynamics, our study showed that such a renal-selective dose did not exist. Furthermore, different doses of dopamine have been investigated in different studies. To our knowledge this is first study examining different doses of dopamine in patients undergoing mechanical ventilation. However, all of our patients received thoracic extradural analgesia with bupivacaine and sufentanil. The resulting sympathetic block may interfere with the distribution of flow and therefore the RBF/CO ratio. Vascular DA1 receptor stimulation results in predominant post-glomerular vasodilatation by direct vasodilatation of the efferent arterioles. 9 18 Because of this mechanism, a preferential increase in RBF has been observed in heart failure patients and in healthy subjects. 6-9 16 The results in our patients suggest that the renal vasodilating effects were outweighed by the systemic effects and were not caused by absent or decreased sympathetic innervation of the kidney, as in kidney transplant recipients a specific renal vasodilating effect of dopamine 2 g kg 91 min 91 is still present (assuming the absence of sympathetic innervation in transplanted kidneys). 21 However, the filtration fraction in our patients was lower than that reported in healthy volunteers and (especially) heart failure patients, [8] [9] [10] which makes a further decrease in filtration fraction as an indication of specific renal vasodilatation more difficult to achieve.
If an increase in RBF and GFR is considered the goal of treatment, our data indicate that 4 g kg 91 min
91 is the optimal dose of those studied. However, this is no reason to give dopamine and should not be considered as the "renal dose". Dopamine increases stroke volume and cardiac output in a dose-dependent manner, with a maximal increase with the highest dose (8 g kg 91 min
). Heart rate increased only with the highest dose of dopamine (8 g kg 91 min
). The positive inotropic effect of dopamine is caused not only by its direct ␤1-agonist activity, but also by inhibition of uptake-1. 22 Uptake-1 inhibition of dopamine may be involved in the increase in plasma concentrations of noradrenaline. Furthermore, as dopamine is a precursor of noradrenaline, stimulation of endogenous noradrenaline formation cannot be excluded. Additionally, dopamine may enhance release of noradrenaline via ␤2-receptor stimulation. We found no effects on plasma renin activity or adrenaline. Although DA1 receptor stimulation can increase PRA, 9 evidence exists that balanced DA1 and DA2 receptor stimulation does not alter PRA. 10 The most important stimulus for an increase in adrenaline concentration is hypoglycaemia and some evidence suggests that stimulation of adrenal DA2 receptors, present on chromaffin cells, induces inhibition of adrenaline release. 23 This may explain why no increase in plasma concentrations of adrenaline was observed.
The reduction in systemic and pulmonary vascular resistance was an unexpected finding in our study. Several mechanisms may be involved; first, all patients received thoracic extradural analgesia, which causes sympathetic block. The influence of dopamine on ganglionic receptors is therefore modified. Second, DA1 receptor-mediated effects, causing vasodilatation, may be involved and override direct ␣1-receptor-mediated vasoconstrictive effects, even at this dose. Rajfer and colleagues 24 observed a decrease in vascular resistance with increasing plasma dopamine concentrations, with administration of levodopa, a dopamine prodrug. Lundberg and colleagues also observed a decrease in systemic vascular resistance during infusion of dopamine. 25 Although our study was uncontrolled, recovery of all variables to (almost) baseline values after stopping dopamine infusion indicated a drug-related and not time-related effect. Our study further emphasizes the different effects of dopaminergic drugs in different categories of patients, as we and others have shown previously. 10 26 27 
